Results 251 to 260 of about 435,750 (350)

The Disordered Region of ASXL1 Acts as an Auto‐Regulator Through Condensation

open access: yesAdvanced Science, EarlyView.
ASXL1's long IDR encodes an electrostatic “basic platform + acidic brake” that autoregulates condensation. Truncation at a clinical hotspot lifts this brake, forming condensates that retarget BRD2, remodel local chromatin accessibility, and impair neutrophil maturation.
Xiao Fang, Qiwei Li, Wenqing Zhang
wiley   +1 more source

A Genetically Encoded, Phage-Displayed Cyclic-Peptide Library. [PDF]

open access: yesAngew Chem Int Ed Engl, 2019
Wang XS   +10 more
europepmc   +1 more source

Genomics Insights Into High‐Latitude Adaptation of Tibetan Macaques

open access: yesAdvanced Science, EarlyView.
Tibetan macaques exhibit unique adaptations to cold, high‐latitude environments, including shortened tails and enhanced fat storage. Genomic analyses reveal a species‐specific TBX6 mutation linked to tail reduction and selection on lipid metabolism genes.
Rusong Zhang   +12 more
wiley   +1 more source

Development of Endogenous Protein Probes for Characterizing Surface Proteins and Cellular Interactors of Extracellular Vesicles

open access: yesAdvanced Science, EarlyView.
The proximity labeling enzyme APEX2 is displayed on extracellular vesicle (EV) surfaces via genetic fusion with EV‐sorting scaffolds, enabling in situ biotinylation of native surface proteins, adsorbed corona components, and interacting cellular proteins.
Wenyi Zheng   +5 more
wiley   +1 more source

Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome

open access: yesAdvanced Science, EarlyView.
Pharmacological SUMOylation inhibition (SUMOi) counteracts tumor immune evasion by unmasking an immunogenic HLA‐I peptide and neoepitope repertoire. By restoring HLA‐I ligand availability through increased antigen processing and presentation, enhanced proteasomal cleavage, and modulated TAP1 peptide affinity, SUMOi boosts tumor immunogenicity ...
Uta M. Demel   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy